Industry Report on Glioblastoma Multiforme(GBM)- Pipeline Review, H1 2016

​Glioblastoma Multiforme(GBM)- Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Glioblastoma Multiforme (GBM) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

To access full report with TOC, please visit ​Glioblastoma Multiforme(GBM)- Pipeline Review, H1 2016.

Scope

- The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM)
- The report reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

AbbVie Inc. Activartis Biotech GmbH Aduro BioTech, Inc. Advanced Accelerator Applications S.A. Advanced Cancer Therapeutics Advantagene, Inc. Advenchen Laboratories, LLC Affimed GmbH Agenus, Inc. Amal Therapeutics SA Ambrx, Inc. Amgen Inc. Ampio Pharmaceuticals, Inc. AngioChem Inc. APIM Therapeutics AS Apogenix GmbH Ariad Pharmaceuticals, Inc. Astellas Pharma Inc. Axelar AB Basilea Pharmaceutica AG Batu Biologics, Inc. BeiGene, Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###